5430642022-04-012022-06-305430642022-04-012022-06-30in-bse-fin:OtherExpenses1Member5430642022-04-012022-06-30in-bse-fin:OtherExpenses2Member5430642022-04-012022-06-30in-bse-fin:OtherExpenses3Member5430642022-04-012022-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

543064

SUVENPHAR

NOT LISTED

INE03QK01018

SUVEN PHARMACEUTICALS LIMITED

Equity

2022-04-01

2023-03-31

2022-08-08

2022-08-01

INR

Lakhs

First quarter

Single segment

Contract Development and Manufacturing Operations (CDMO)

2022-08-08

11:30:00

2022-08-08

12:50:00

Not applicable

2022-04-01

2022-06-30

Unaudited

Standalone

3387991000

108975000

3496966000

1122940000

-156413000

247926000

14325000

105478000

626141000

1960397000

1536569000

388810000

7242000

396052000

1140517000

-1907000

1138610000

254565000

4.48

1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8 Aug, 2022. The above results have been subjected to limited review by the statutory auditors of the company. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma,Inc.,USA. & Casper Pharma Pvt Ltd, (Casper Pharma) effective 22 April' 2022 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q3 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsidiary, Suven pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on Such Dividend by our subsidiary. 6) The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to $35.00 Mn) in Rising Pharma Holdings, Inc., USA on 13 Dec 2021 and accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a 7% stake valued at $15.803 Mn in Raisin Aggregators L.P effective 13 Dec 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 30 June 2022. 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, and SEZ company engaged in formulations business for USD.20.50Min and has become a Wholly Owned Subsidiary of the Company w.e.f 22 nd April 2022. Also subscribed the right issue in the ratio of 1:4 on 22 Jun 2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs. 8) The US Food and Drug Administration (USFDA) completed pre-approval inspection at Casper Pharma formulations manufacturing facility. The inspection was conducted from 25 through 29, July 2022. The audit was part of the agency's inspection for three product applications filed and slated to be manufactured at this site. The audit completed successfully with Zero observations and at the end of the inspection no form 483 was issued by USFDA. 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

R & D Expenses

22323000

Manufacturig Expenses

413869000

Other Expenses

189949000

Items that will not be reclassified to profit or loss

-2548000

-641000